Fujian Haixi Pharma says FDA grants fast track status to HX9428 for wet AMD

• Fujian Haixi Pharmaceuticals’ oral small-molecule HX9428 won FDA Fast Track designation for neovascular age-related macular degeneration.
• Status supports closer FDA engagement, potential priority review eligibility, accelerated approval pathways, rolling NDA submissions.
• Program completed Phase 1 in China; running Phase 2 studies. FDA also cleared a US Phase 2 trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260817-12287298), on August 17, 2026, and is solely responsible for the information contained therein.